We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 17 november 2017

The Lancet: [Articles] Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opi...

[Articles] Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial
In this population it is more difficult to initiate patients to XR-NTX than BUP-NX, and this negatively affected overall relapse. However, once initiated, both medications were equally safe and effective. Future work should focus on facilitating induction to XR-NTX and on improving treatment retention for both medications.
Read more

[Comment] Extended-release naltrexone: good but not a panacea
Unlike other addictions, opioid-use disorder has several highly effective medication treatments available, in particular methadone, buprenorphine, and naltrexone.1–3 Methadone is the least accessible or acceptable of these in many settings, so providers and patients are often faced with a choice between buprenorphine-naloxone (BUP-NX) and extended-release naltrexone injection (XR-NTX).
Read more

[Comment] Medications for opioid use disorder: bridging the gap in care
For the past two decades, the USA has been in the throes of an opioid crisis marked by a rising number of deaths; in 2016, opioids were responsible for most of the nation's estimated 64 000 fatal drug overdoses.1 The problem began with overprescribing of opioid analgesics in the 1990s, which exposed pain patients to the risks of addiction and produced large surpluses of pain pills that were diverted for misuse by the larger community. Additionally, the escalating numbers of opioid-addicted Americans led to increased HIV and hepatitis C transmission among people who misuse these drugs by injecting them2 and increased numbers of infants born dependent on opioids as a result of the mother's opioid use (neonatal abstinence syndrome).
Read more

[Department of Error] Department of Error
Lu J, Lu Y, Wang X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project). Lancet 2017; published online Oct 25. http://dx.doi.org/10.1016/S0140-6736(17)32478-9—In figure 1 of this Article, the labels 'Awareness' and 'Control' should be swapped round. This correction has been made to the print version as of Nov 14, 2017.
Read more

[Comment] Retraction and republication—Misoprostol drug to be withdrawn from French market
On Oct 28, 2017, The Lancet published the World Report "Misoprostol drug to be withdrawn from French market" as an epage.1 After further information was provided to us, The Lancet Editors have decided to retract this World Report, and republish it having removed the information that we believe to be inaccurate.2 The old version of the World Report will be added to a webappendix attached to the new version and will be marked as retracted. Additionally, the following sentence should have read: "One issue is that the 200 μg Cytotec tablets have to be split into eight identical sections to obtain the 25 μg dose for labour induction, which means 'there is a risk of overdose', says Martin".
Read more